|

LCAR-AIO T cells Clinical Trials

2 actively recruiting trials

Pipeline

Early 1: 1Phase 1: 1

Top Sponsors

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology2

Indications

  • Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (MOGAD)1
  • Neuromyelitis Optica Spectrum Disease (NMOSD)1
  • Multiple Sclerosis (MS)1
  • Systemic Lupus Erythematosus (SLE)1
  • Lupus1

Other2 trials

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Phase 1
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.